Immunai expanded its collaboration with AstraZeneca to extend usage of its AMICA-OS AI platform across oncology drug development. The parties described the deal as worth up to $37.5 million, covering additional support for biomarker discovery, patient stratification, and mechanism-of-action analysis. The expansion continues AstraZeneca’s adoption of AMICA-OS for clinical and translational decision support, where AI is used to interpret complex data layers that connect tumor biology to therapy response. The companies framed the platform’s role as helping accelerate identification of analytic signals across investigational programs. For Immunai, the expanded agreement reinforces a strategy of selling AI workflow access to large pharma teams rather than running proprietary wet-lab development. It also signals that digital oncology analytics remains a budget priority among drugmakers even amid tighter discretionary spending.